>>Teva reported today that the CoGenesys acquisition closed (#msg-26992602), and evidently there was no valuation adjustment. I would consider this bullish for Albuferon.<<
It is clearly bullish for the hypothesis that the 'problem' with Albuferon is not a(n albumin-fusion technology) class effect. But I don't see why the acquisition closing w/o adjustment is bullish for Albuferon in particular ... given that Albuferon wasn't included in the Teva-CoGenesys deal.
Market Data 
Markets 
AI
